课题基金 / 基金详情

项目摘要

项目成果

ROBERT A SEDER的其他基金

相似基金

相关文献

中文摘要
翻译
利什曼原虫感染在世界范围内引起严重的发病率和死亡率。感染宿主的利什曼原虫种类的类型和宿主产生的免疫反应决定了所看到的临床疾病的谱。特别是,T细胞产生细胞因子的模式对保护至关重要。目前还没有易于管理、有效和具有成本效益的利什曼原虫疫苗。在过去的一年里,我们开发了使用聚合物和免疫增强剂递送疫苗的新方法,它们共同产生更强大的免疫反应,但限制了任何毒性。
英文摘要
Infection with Leishmania causes significant morbidity and mortality worldwide. The type of Leishmania species infecting the host and the immune response generated by the host determines the spectrum of clinical disease that is seen. In particular, the pattern of cytokine production from T cells is critical for protection. At present there is no vaccine for Leishmania that is easy to administer, efficacious, and cost effective. Over the past year we developed new way to deliver vaccines using polymers and immune enhances that together lead to more robust immune responses but limits any toxicity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
VACCINE DEVELOPMENT FOR TUBERCULOSIS
  • 批准号:
    7958684
  • 项目类别:
  • 资助金额:
    $5.57万
  • 财政年份:
    2009
  • 负责人:
    ROBERT A SEDER
  • 依托单位:
DNA VACCINATION FOR PREVENTION OF VIRAL, PARASITIC AND MYCOBACTERIAL INFECTION
Development Of A Vaccine For Leishmania Major Infection
Development Of A Vaccine For Leishmania Major Infection
海外基金